Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Yusuke, Okuwaki"'
Autor:
Shigehiro Kokubu, Haruki Uojima, Tomoyoshi Inoue, Wasaburo Koizumi, Hisashi Hidaka, Takahide Nakazawa, Juichi Takada, Akitaka Shibuya, Keiji Matsunaga, Keiko Yamane, Kousuke Kubota, Yusuke Okuwaki, Yoshiaki Tanaka
Publikováno v:
Hepatology Research. 47:1118-1126
Aim To examine whether superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance imaging (MRI) can be used to assess the malignant potential of hepatic hypovascular nodules showing hypointensity during the hepatobiliary phase (HBP) on gadoxetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df8fda701f2236057eaadcecc40b795e
https://doi.org/10.1111/hepr.12850
https://doi.org/10.1111/hepr.12850
Autor:
Hisashi Hidaka, Yusuke Okuwaki, Keiko Yamane, Yasuhiro Matsumoto, Kousuke Kubota, Tomoyoshi Inoue, Juichi Takada, Keiji Matsunaga, Tsutomu Minamino, Wasaburo Koizumi, Yoshiaki Tanaka, Takahide Nakazawa, Akitaka Shibuya
Publikováno v:
Hepatology Research. 46:559-564
Aim Portopulmonary venous anastomoses (PPVA) are shunts between esophageal varices and pulmonary veins. Because PPVA can cause serious complications at the time of sclerotherapy for esophageal varices, it is essential to confirm the existence of any
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d60ab6d2e84b1563754946995e5421c4
https://doi.org/10.1111/hepr.12591
https://doi.org/10.1111/hepr.12591
Autor:
Michiko Yanagihara, Hisashi Hidaka, Tsutomu Minamino, Juichi Takada, Takahide Nakazawa, Yusuke Okuwaki, Yoshiaki Tanaka, Wasaburo Koizumi, Akitaka Shibuya, Shigeru Fujii
Publikováno v:
Hepatology Research. 45:976-985
Aim Early evaluation of the response to sorafenib for patients with hepatocellular carcinoma (HCC) remains unclear. This prospective study investigated the early evaluation of the efficacy of sorafenib in patients with advanced HCC using duplex Doppl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c160c13c556b4246e81f771b37fbdf05
https://doi.org/10.1111/hepr.12440
https://doi.org/10.1111/hepr.12440
Autor:
Yusuke Okuwaki, Tomoyoshi Inoue, Juichi Takada, Kaoru Fujii, Takahide Nakazawa, Reiko Woodhams, Shigehiro Kokubu, Kousuke Kubota, Yoshiaki Tanaka, Haruki Uojima, Akitaka Shibuya, Wasaburo Koizumi, Keiko Yamane, Hisashi Hidaka, Keiji Matsunaga
Publikováno v:
Hepatology Research. 48
Aim Transcatheter arterial chemoembolization (TACE) has been recognized as a treatment option for patients with intermediate hepatocellular carcinoma (HCC). This randomized, controlled study compared the local control efficacy of TACE with miriplatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::949bee9ee02694512455c25e880e5573
https://doi.org/10.1111/hepr.12933
https://doi.org/10.1111/hepr.12933
Autor:
Hisashi Hidaka, Michihiro Suzuki, Kotaro Matsunaga, Satoshi Morita, Masataka Taguri, Takahide Nakazawa, Manabu Morimoto, Yusuke Okuwaki, Kazushi Numata, Masaaki Kondo, Satoshi Kobayashi, Chiaki Okuse, Katsuaki Tanaka, Shinichi Ohkawa
Publikováno v:
Hepatology Research. 45:279-287
Aim Patients with hepatocellular carcinoma (HCC) who receive an initial full dose of sorafenib (800 mg/day) often require a decreased dose (400 mg/day) or discontinuation of therapy because of severe adverse events. We conducted a retrospective analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::814ae4b5c09b93b5445a1e8d0156f9fa
https://doi.org/10.1111/hepr.12354
https://doi.org/10.1111/hepr.12354
Autor:
Masaaki Watanabe, Shigehiro Kokubu, Wasaburo Koizumi, Shouko Komori, Kazushige Hayakawa, Tsutomu Minamino, Hajime Yamamoto, Juichi Takada, Yusuke Okuwaki, Yoshiaki Tanaka, Hisashi Hidaka, Akitaka Shibuya, Takahide Nakazawa
Publikováno v:
Journal of Gastroenterology and Hepatology. 29:352-357
Background and Aim To examine the efficacy and outcomes of radiotherapy (RT) in patients who have hepatocellular carcinoma with invasion to intrahepatic large vessels (IHLVs). Methods Sixty-seven patients who had advanced hepatocellular carcinoma wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eab77dde58eea00087e9636af8727f71
https://doi.org/10.1111/jgh.12333
https://doi.org/10.1111/jgh.12333
Autor:
Wasaburo Koizumi, Akitaka Shibuya, Hisashi Hidaka, Masaaki Watanabe, Takahide Nakazawa, Shigehiro Kokubu, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino
Publikováno v:
European Journal of Gastroenterology & Hepatology. 25:683-689
To determine the value of early alterations of the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for predicting the outcomes of patients with advanced hepatocellular carcinoma (HCC) who receive sorafenib.Tumor response, over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffd5448073fa579f6b7443e4b0efb34d
https://doi.org/10.1097/meg.0b013e32835d913b
https://doi.org/10.1097/meg.0b013e32835d913b
Autor:
Yoshiaki Tanaka, Yasuhiro Matsumoto, Takahide Nakazawa, Yusuke Okuwaki, Wasaburo Koizumi, Akitaka Shibuya, Makoto Ohbu, Juichi Takada, Tsutomu Minamino, Masaaki Watanabe, Hisashi Hidaka
Publikováno v:
Open Journal of Gastroenterology. :128-133
Aim: We evaluated the long-term effects of olmesartan, an angiotensin type 1 receptor blocker, in patients with non-alcoholic steatohepatitis (NASH) complicated with hypertension. Methods: All patients were given a standard calorie diet and exercise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f609c64b563b3f90ec91b637513e4991
https://doi.org/10.4236/ojgas.2013.32021
https://doi.org/10.4236/ojgas.2013.32021
Autor:
Hisashi Hidaka, Akitaka Shibuya, Juichi Takada, Wasaburo Koizumi, Toru Kaneko, Tsutomu Minamino, Takahide Nakazawa, Masaaki Watanabe, Yoshiaki Tanaka, Yusuke Okuwaki
Publikováno v:
Journal of Gastroenterology. 47:1030-1035
Sorafenib is currently in clinical use as an oral multikinase inhibitor that blocks tumor growth and cell proliferation in advanced hepatocellular carcinoma (HCC). It has been demonstrated in a translating study that sorafenib had a beneficial effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb52a7a6879a36c009348edf52609c3
https://doi.org/10.1007/s00535-012-0563-6
https://doi.org/10.1007/s00535-012-0563-6
Autor:
Masaaki Watanabe, Yusuke Okuwaki, Manabu Ohsaka, Hisashi Hidaka, Wasaburo Koizumi, Masaaki Higashihara, Mikio Danbara, Yuhko Tsunoda, Ryuji Ishii, Ryouichi Horie, Tsutomu Minamino, Yoshiaki Tanaka, Juichi Takada, Akitaka Shibuya, Takahide Nakazawa
Publikováno v:
Liver International. 31:340-347
Background and aim: De novo hepatitis B virus (HBV)-related hepatitis is a well-known fatal complication following chemo-immunosuppressive therapy in patients with past HBV infection (HB surface antigen and serum HBV DNA negative, but HB core antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25136003b9ded00c66bf44a028ad23df
https://doi.org/10.1111/j.1478-3231.2010.02417.x
https://doi.org/10.1111/j.1478-3231.2010.02417.x